1
|
Song JS, Chung HC, Sohn S, Kim YJ. Effects of psychological behaviour management programme on dental fear and anxiety in children: A randomised controlled clinical trial. Eur J Paediatr Dent 2020; 21:287-291. [PMID: 33337904 DOI: 10.23804/ejpd.2020.21.04.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
AIM A psychological behaviour management programme with information and communications technology was developed that includes symbolic modelling, tell-show-do, positive reinforcement and distraction, and provides real-time treatment information. We hypothesised that the programme would help patients feel less stressed and show less uncooperative behaviours and subjective pain. MATERIALS AND METHODS Forty-eight paediatric patients were recruited from May 2016 to January 2017, and randomly divided into a control group and an experimental group. In the control, patients watched cartoon animations during the first and second treatments. The experimental group watched cartoon animations during the first treatment, and they used the programme during the second treatment. To measure stress, uncooperative behaviour and subjective pain, we recorded the heart rate, Procedure Behaviour Checklist (PBCL) and Wong and Baker's Faces Pain Rating Scale (FPRS). RESULTS The experimental group resulted in a significantly lower mean heart rate, uncooperative behaviour and subjective pain in the second treatment than did the control group (p<0.001). The differences in heart rate and uncooperative behaviour between the treatments were also significantly greater in the experimental group than in the control group (p<0.001). CONCLUSION The programme was effective in relieving fear and anxiety as well as learning cooperative behaviour.
Collapse
Affiliation(s)
- J-S Song
- DDS, PhD, Assistant professor of the department of Paediatric Dentistry, Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Republic of Korea
| | - H-C Chung
- MS, Computer scientist in the Culture Technology, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
| | - S Sohn
- MA, Computer-mediated communication researcher in graduate school of Communication and Arts, Yonsei University, Seoul, Republic of Korea
| | - Y-J Kim
- DDS, PhD, Professor and Chair of the department of Paediatric Dentistry, Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Republic of Korea
| |
Collapse
|
2
|
Lee S, Kim A, Sohn S, Kim H, Seok S, Shin J, Kim D. 227 The effect of endothelial precursor cell-conditioned media on keratinocytes and 3D skin models. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3
|
Kim JY, Lee EJ, Park KH, Im SA, Kim SB, Sohn SH, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH, Park YH. Abstract P3-11-07: Exploratory biomarker analysis from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)- negative metastatic breast cancer(MBC): Korean cancer study group trial (KCSG BR13-11). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-11-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction : A phase II, multicenter, randomized clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) found EG was less neurotoxic, but had similar efficacy of PG. In this study, we performed exploratory biomarker analysis of the impact of genetic alterations on the efficacy according to EG and PG chemotherapy.
Methods : This biomarker study was conducted using tumor samples from 40patients. When tissue collection was possible after disease progression, we performed paired sample analysis. Tumor DNA and RNA were extracted from formalin-fixed, paraffin-embedded tissues. To perform targeted deep sequencing, we used CancerScanTM, a 375 cancer gene panel. And we performed an nCounter expression assay for gene expression analysis using 730 PanCancer panel and 730 Immune panel.
Results: In total, we obtained 44 tissue samples from 40 patients. Twenty two patients were assigned in EG arm and 18 patients were in PG arm. Thirty-eight were at baseline and six after disease progression. Gene expression assay were performed in 44 tissue samples but only 31 samples were possible to be targeted deep sequencing.
We performed differently expressed gene(DEG) analysis for detecting the association between level of gene expression and disease progression. In this analysis, high expression of CCNE1, TGFB4 and BAMBI and low expression of DDB2, CD14 and SHC3 were associated with disease progression among 730 PanCancer panel genes (p<0.05, respectively). In terms of immune panel genes, most of immune related genes were highly expressed in a group without disease progression compared with that with disease progression. Only 2 genes, C8G and CD24 were highly expressed in a group with disease progression. Paired sample analysis showed that expression levels of THBS4 and CD27 decreased after disease progression while those of CCNE2 and FGFR4 increased.
In targeted deep sequencing, FAT3 (42.3%) was most frequently mutated gene followed by PKHD1, PIK3CA and TP53. Among mutated genes, EWSR1 mutation and upstream mutation of ETV1 were associated with disease progression, respectively (p<0.05, respectively). In mutation signature analysis, signature 1 (S, age related), S3(homologous recombination deficiency, HRD), S6 (mismatch repair, MMR), S20(MMR) and S21(microsatellite instability, MSI) were enriched in this population. Mutation signature 3 related to short disease free survival (p=0.0026).
Conclusion: In gene expression analysis, high expression of TGF-B signaling pathway related genes was associated with disease progression while high expression of immune related genes were related to prolonged disease free survival. In mutation analysis, EWSR1 and ETV1 mutations indicated short disease free interval and HRD mutation signature was also related to poor prognosis.
Citation Format: Kim J-Y, Lee EJ, Park KH, Im S-A, Kim S-B, Sohn SH, Lee KS, Chae YS, Lee KH, Kim JH, Im Y-H, Kim T-Y, Lee K-H, Ahn J-H, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH, Park YH. Exploratory biomarker analysis from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)- negative metastatic breast cancer(MBC): Korean cancer study group trial (KCSG BR13-11) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-11-07.
Collapse
Affiliation(s)
- J-Y Kim
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - EJ Lee
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - KH Park
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - S-A Im
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - S-B Kim
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - SH Sohn
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - KS Lee
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - YS Chae
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - KH Lee
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - JH Kim
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - Y-H Im
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - T-Y Kim
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - K-H Lee
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - J-H Ahn
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - GM Kim
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - IH Park
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - SJ Lee
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - HS Han
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - SH Kim
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - KH Jung
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| | - YH Park
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Center for Breast Cancer, National Cancer Center, Goyang, Korea; Kyungpook National University Medical Center, Daegu, Korea; Chungbuk National University Hospital, Cheongju, Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
| |
Collapse
|
4
|
Chun BC, Hong K, Sohn S, Hwnag H. El Nino southern oscillation affects on influenza peak activity seasons: comparison of the effects between Korea and the USA with surveillance data from 2005 to 2018. Int J Infect Dis 2019. [DOI: 10.1016/j.ijid.2018.11.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
5
|
Affiliation(s)
- S Sohn
- Gyeongnam National University of Science and Technology,Jinju, Republic of Korea
| | - J Park
- Gyeongnam National University of Science and Technology,Jinju, South Korea
| |
Collapse
|
6
|
Sohn S, Bang M, Cho E. WPSI-3 Characteristics of the feather developing pattern of early-feathering chicks and late-feathering chicks. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.1119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- S Sohn
- Gyeongnam National University of Science and Technology,Jinju, Republic of Korea
| | - M Bang
- Gyeongnam National University of Science and Technology,Jinju, South Korea
| | - E Cho
- Gyeongnam National University of Science and Technology,Jinju, South Korea
| |
Collapse
|
7
|
Wi C, Krusemark EA, Voge G, Sohn S, Liu H, Ryu E, Park MA, Castro‐Rodriguez JA, Juhn YJ. Usefulness of asthma predictive index in ascertaining asthma status of children using medical records: An explorative study. Allergy 2018; 73:1276-1283. [PMID: 29319899 DOI: 10.1111/all.13403] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/22/2017] [Indexed: 11/29/2022]
Abstract
BACKGROUND Frequent wheezing in original asthma predictive index (API) was defined by parental report of recurrent wheezing within 1 year during the first 3 years of life. The nature of frequent wheezing in children, particularly aged over 3 years, has not been studied. We aimed to assess the frequency and interval of wheezing to define frequent wheezing in ascertaining asthma for children using medical records. METHODS Among children who participated in a previous study (n = 427), all wheezing episodes documented in medical records were collected for children who had ≥2 wheezing episodes PLUS met one major criterion or two minor criteria of API. We compared the distribution of known risk factors for asthma between subjects having two consecutive wheezing episodes with shorter interval (≤1 year) compared to those with longer interval (1 to 3 years). RESULTS A total of 62 children met API at median age of 2.3 years. During follow-up period (median age: 11.3 years), a total of 198 wheezing episodes were observed. 81% of wheezing intervals were within 3 years from the earlier wheezing episode, including 60% within 1 year. Children who met API based on 1-year interval (n = 40) vs 1- to 3-year interval (n = 13) appeared to be similar in regard to the known risk factors for asthma. CONCLUSIONS Our exploratory study finding suggests that children who had frequent wheezing episodes with longer interval (<3 years) need to be considered to be determined as asthma cases when API is applied to retrospective medical records. Prospective studies with a larger sample size need to replicate this finding.
Collapse
Affiliation(s)
- C.‐I. Wi
- Department of Pediatric and Adolescent Medicine Mayo Clinic Rochester MN USA
- Asthma Epidemiology Research Unit Mayo Clinic Rochester MN USA
| | - E. A. Krusemark
- Department of Pediatric and Adolescent Medicine Mayo Clinic Rochester MN USA
- Asthma Epidemiology Research Unit Mayo Clinic Rochester MN USA
| | - G. Voge
- Department of Pediatric and Adolescent Medicine Mayo Clinic Rochester MN USA
- Asthma Epidemiology Research Unit Mayo Clinic Rochester MN USA
- Division of Neonatology Children's Hospitals and Clinics of Minnesota Minneapolis MN USA
| | - S. Sohn
- Division of Biomedical Statistics and Informatics Mayo Clinic Rochester MN USA
| | - H. Liu
- Division of Biomedical Statistics and Informatics Mayo Clinic Rochester MN USA
| | - E. Ryu
- Asthma Epidemiology Research Unit Mayo Clinic Rochester MN USA
- Division of Biomedical Statistics and Informatics Mayo Clinic Rochester MN USA
| | - M. A. Park
- Division of Allergic Diseases Mayo Clinic Rochester MN USA
| | - J. A. Castro‐Rodriguez
- Division of Pediatrics School of Medicine Pontificia Universidad Catolica de Chile Santiago Chile
| | - Y. J. Juhn
- Asthma Epidemiology Research Unit Mayo Clinic Rochester MN USA
- Department of Pediatric and Adolescent Medicine/Internal Medicine Mayo Clinic Rochester MN USA
| |
Collapse
|
8
|
Kim D, Kim H, Sohn S, Kim A, Baek S, Lee C, Jeong I, Kim T. 688 Epithelial precursor cell-conditioned media ameliorates UV irradiation-induced extracellular matrix damage in human skin equivalents. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Doebel T, Voisin B, Kelly M, Kobayashi T, Sohn S, Kelley M, Nagao K. 628 Heterogeneity and cytokine-dependency of macrophages in skin layers. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
10
|
Kobayashi T, Truong A, Shih H, Doebel T, Voisin B, Woodring T, Sohn S, Kennedy E, Jo J, Moro K, Leonard W, Kong H, Nagao K. 604 Spatial heterogeneity and functional diversity of innate lymphoid cells in the skin. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Sohn S, Chung J, Ji S, Kim J, Yu J, Kim A, Kang S. 149 The protective effects of stem cell-derived epidermal progenitor cell-conditioned media against oxidative stress in human dermal fibroblasts. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Sohn S, Park Y, Srikanth S, Arai A, Song M, Yu B, Shin KH, Kang MK, Wang C, Gwack Y, Park NH, Kim RH. The Role of ORAI1 in the Odontogenic Differentiation of Human Dental Pulp Stem Cells. J Dent Res 2015; 94:1560-7. [PMID: 26403672 DOI: 10.1177/0022034515608128] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Pulp capping, or placing dental materials directly onto the vital pulp tissues of affected teeth, is a dental procedure that aims to regenerate reparative dentin. Several pulp capping materials are clinically being used, and calcium ion (Ca(2+)) released from these materials is known to mediate reparative dentin formation. ORAI1 is an essential pore subunit of store-operated Ca(2+) entry (SOCE), which is a major Ca(2+) influx pathway in most nonexcitable cells. Here, we evaluated the role of ORAI1 in mediating the odontogenic differentiation and mineralization of dental pulp stem cells (DPSCs). During the odontogenic differentiation of DPSCs, the expression of ORAI1 increased in a time-dependent manner. DPSCs knocked down with ORAI1 shRNA (DPSC/ORAI1sh) or overexpressed with dominant negative mutant ORAI1(E106Q) (DPSC/E106Q) exhibited the inhibition of Ca(2+) influx and suppression of odontogenic differentiation and mineralization as demonstrated by alkaline phosphatase (ALP) activity/staining as well as alizarin red S staining when compared with DPSCs of their respective control groups (DPSC/CTLsh and DPSC/CTL). The gene expression for odontogenic differentiation markers such as osteocalcin, bone sialoprotein, and dentin matrix protein 1 (DMP1) was also suppressed. When DPSC/CTL or DPSC/E106Q cells were subcutaneously transplanted into nude mice, DPSC/CTL cells induced mineralized tissue formation with significant increases in ALP and DMP1 staining in vivo, whereas DPSC/E106Q cells did not. Collectively, our data showed that ORAI1 plays critical roles in the odontogenic differentiation and mineralization of DPSCs by regulating Ca(2+) influx and that ORAI1 may be a therapeutic target to enhance reparative dentin formation.
Collapse
Affiliation(s)
- S Sohn
- UCLA School of Dentistry, Los Angeles, CA, USA Laboratory of Viral Oncology and Aging Research, UCLA School of Dentistry, Los Angeles, CA, USA
| | - Y Park
- UCLA School of Dentistry, Los Angeles, CA, USA Laboratory of Viral Oncology and Aging Research, UCLA School of Dentistry, Los Angeles, CA, USA
| | - S Srikanth
- Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - A Arai
- UCLA School of Dentistry, Los Angeles, CA, USA Laboratory of Viral Oncology and Aging Research, UCLA School of Dentistry, Los Angeles, CA, USA
| | - M Song
- UCLA School of Dentistry, Los Angeles, CA, USA Laboratory of Viral Oncology and Aging Research, UCLA School of Dentistry, Los Angeles, CA, USA
| | - B Yu
- UCLA School of Dentistry, Los Angeles, CA, USA
| | - K-H Shin
- UCLA School of Dentistry, Los Angeles, CA, USA Laboratory of Viral Oncology and Aging Research, UCLA School of Dentistry, Los Angeles, CA, USA UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA
| | - M K Kang
- UCLA School of Dentistry, Los Angeles, CA, USA Laboratory of Viral Oncology and Aging Research, UCLA School of Dentistry, Los Angeles, CA, USA UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA
| | - C Wang
- UCLA School of Dentistry, Los Angeles, CA, USA UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA
| | - Y Gwack
- Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - N-H Park
- UCLA School of Dentistry, Los Angeles, CA, USA Laboratory of Viral Oncology and Aging Research, UCLA School of Dentistry, Los Angeles, CA, USA UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - R H Kim
- UCLA School of Dentistry, Los Angeles, CA, USA Laboratory of Viral Oncology and Aging Research, UCLA School of Dentistry, Los Angeles, CA, USA UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA
| |
Collapse
|
13
|
Sohn S, Wolf T, Heidler J, Amler N, Schreiter A. Therapiehilfen und Ressourcenverbrauch in der Versorgung der Depression. Dtsch Med Wochenschr 2012. [DOI: 10.1055/s-0032-1323485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
14
|
Park M, Sohn S, Park J, Sohn J. Neural substrates underlying joy among recovering alcoholics. Int J Psychophysiol 2012. [DOI: 10.1016/j.ijpsycho.2012.07.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
15
|
Affiliation(s)
- C. Jacke
- Arbeitsgruppe Versorgungsforschung, Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim/Universität Heidelberg
| | - J. Frech
- Abteilung für Orthopädie und Unfallchirurgie, Bundeswehrzentralkrankenhaus Koblenz
| | - T. Eikmann
- Institut für Hygiene und Umweltmedizin, Universitätsklinikum Gießen und Marburg, Standort Gießen
| | - O. Schöffski
- Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg
| | - H. Klose
- Klinik für Strahlendiagnostik, Universitätsklinikum Gießen und Marburg, Standort Marburg
| | - S. Sohn
- Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg
| |
Collapse
|
16
|
Abstract
SUMMARY
Objective
The purpose of this study was to evaluate the effects of different desensitizing agents on the prevention of root caries when applied to root surfaces.
Materials and Methods
Thirty human roots were sectioned into quarters with a 3 × 4 mm window. A desensitizer (VX, Clinpro™ XT Varnish; SP, Seal & Protect®; or PB, Clearfil™ Protect Bond) was applied to three of the quarters in each window. Teeth were stored separately in water for one day, 30 days, or 60 days. The remaining quarter, without the application of desensitizer, served as a control. After storage in water, all specimens were subjected to pH cycling. Scanning electron microscopy was used to observe the demineralization bands created on the subsurface layer. The weight percentages of fluorine (F), silica, and calcium (Ca) were determined using electron probe microanalysis to quantify the elemental distributions in the root dentin. The concentrations of F released during a pH cycling were measured.
Results
For the control group, the average lesion depth was 18.92 ± 5.42 μm, and the average Ca loss was 15.66% ± 6.80% in the superficial layer and 30.44% ± 9.61% in the subsurface layer. No Ca loss occurred in the desensitizer-treated groups. All desensitizing agents remained intact for at least 60 days. F levels were increased in the hybrid layer but not in the subhybrid area. Outward release of F diminished with time.
Conclusion
The F-containing resin-based desensitizers protected exposed root surfaces from demineralization. F liberated from the desensitizers was detected only at minimal levels.
Collapse
|
17
|
Sohn S, Lee ES, Bang D. Learning from HSV-infected mice as a model of Behçet's disease. Clin Exp Rheumatol 2012; 30:S96-S103. [PMID: 22766172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2011] [Accepted: 11/29/2011] [Indexed: 06/01/2023]
Abstract
Several animal models of Behçet's disease (BD) have been proposed according to putative etiology. Among these models, the herpes simplex virus (HSV)-induced model produced the most similar disease attributes observe in patients. Inoculation of HSV type 1 to the scratched earlobe of mice produced the appropriate symptoms, including oral, genital, and skin ulcers, eye lesions, arthritis, and intestinal involvement. This HSV-induced BD model is the only continuously used model, to which various therapeutic modalities have been applied.
Collapse
Affiliation(s)
- S Sohn
- Laboratory of Cell Biology, Ajou University School of Medicine, Suwon 433-721, Korea.
| | | | | |
Collapse
|
18
|
Emmert M, Gemza R, Schöffski O, Sohn S. [Public reporting in health care: the impact of publicly reported quality data on patient steerage]. Gesundheitswesen 2011; 74:e25-41. [PMID: 21866496 DOI: 10.1055/s-0031-1285857] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
BACKGROUND Public reporting (PR) has been gaining more weight as a mechanism for patient steerage. According to the theory of PR, patients use information about the quality of health care providers before making decisions and selecting health-care providers. This paper contributes further knowledge on the effectiveness of PR and identifies critical success factors. These should be taken into account when implementing PR in the German health care system. METHODOLOGY The peer-reviewed English, Spanish, and German language literature was searched in the following five databases: The Cochrane Library, Medline (via PubMed), ISI Web of Knowledge, EconLit, and PsycINFO (since 2005). In addition, reference lists of the included studies and reviews were screened in order to identify previously published studies. RESULTS In total, 21 studies were identified regarding the impact of 12 different PR instruments on patient steerage. An impact could be demonstrated in 9 studies, 7 studies showed mixed results, while 5 studies could not show any effect on patient steerage. 20 studies were carried out in the US environment, 1 study in Germany. The most researched instrument is the New York State Cardiac Surgery Reporting System (N=8). CONCLUSION PR can be effective in steering patients when seeking a health-care provider, especially for elective procedures. To be successful, information provided must be reliable, easily understandable, should further represent real news, and be disseminated widely. Besides this, it has to be applicable and modifiable according to individual preferences.
Collapse
Affiliation(s)
- M Emmert
- Friedrich-Alexander-Universität Erlangen-Nürnberg, Lehrstuhl für Gesundheitsmanagement, 90403 Nürnberg.
| | | | | | | |
Collapse
|
19
|
Abstract
In this study we found that autotrophic methanococci similar to Methanococcus maripaludis obtained up to 57% of their cellular carbon from exogenous amino acids. About 85% of the incorporation was into protein. Primarily nonpolar and basic amino acids and glycine were incorporated; only small amounts of acidic and some polar amino acids were taken up. An additional 10% of the incorporation was into the nucleic acid fraction. Because little CO(2) was formed from the C-amino acids, little metabolism of the amino acids occurred. Therefore the growth stimulation by amino acids was probably due to the sparing of anabolic energy requirements. Of the amino acids incorporated, only alanine was also a sole nitrogen source for these methanococci. In contrast, Methanococcus vannielii and "Methanococcus aeolicus" are autotrophic methanococci which did not incorporate amino acids and did not utilize alanine as a sole nitrogen source. Although glutamine served as a sole nitrogen source for the autotrophic methanococci and Methanococcus voltae, a heterotrophic methanococcus, growth was due to chemical deamination in the medium. M. voltae requires leucine and isoleucine for growth. However, these amino acids were not significant nitrogen sources, and alanine was not a sole nitrogen source for the growth of M. voltae. The branched-chain amino acids were not extensively metabolized by M. voltae. Pantoyl lactone and pantoic acid were readily incorporated by M. voltae. The intact vitamin pantothenate was neither stimulatory to growth nor incorporated. In conclusion, although amino acids and vitamins are nutritionally important to both autotrophic and heterotrophic methanococci, generally they are not subject to extensive catabolism.
Collapse
Affiliation(s)
- W B Whitman
- Department of Microbiology, University of Georgia, Athens, Georgia 30602
| | | | | | | |
Collapse
|
20
|
Lim S, Lee K, Joo Y, Lee W, Yoon S, Sohn S, Bae S, Hyun M, Kim H, Eom H. The importance of imatinib dose intensity in imatinib plus combination chemotherapy in newly diagnosed Ph+ ALL. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.6563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Kim Y, Kang B, Kim J, Chae Y, Sohn S, Kim S, Lee S, Jeong J, Baek J. Clinical significance of hypoxia-inducible factor-1 alpha gene polymorphisms in patients with colorectal cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Kang B, Kim J, Chae Y, Sohn S, Kim S, Lee S, Jeong J, Baek J. Impact of insulin-like growth factor gene polymorphisms on survival of patients with colorectal cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Kim S, Kang B, Chae Y, Kim J, Kim Y, Sohn S. Prognostic value of the absolute lymphocyte count reduction in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Chae Y, Kim J, Sohn S, Kang B, Ryoo H, Bae S, Choi G, Baek J, Kim Y, Cho Y. Association of MGMT-535G>T polymorphism with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Lee S, Joo Y, Lee K, Kim K, Ahn J, Sohn S, Kim H, Choi Y, Park J, Lee G. High-dose of daunorubicin as induction treatment for adults with newly diagnosed Philadelphia-negative acute lymphoblastic leukemia. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.6589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
|
27
|
Sohn J, Park M, Sohn S, Park J, Eum Y, Kim S, Yu I. Compensatory Mechanisms Associated with Verbal Working Memory in the Brain among Individuals with Alcohol Use Disorders. Neuroimage 2009. [DOI: 10.1016/s1053-8119(09)71962-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
28
|
Jeong J, Chae Y, Kim J, Sohn S, Park H, Park J, Yang J, Park I, Lee Y. Association between P53 expression or TP53 codon 72 polymorphism and prognosis in patients with operated invasive breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22175 Background: The present study analyzed the impact of p53 expression and TP53 codon 72 polymorphism on the prognosis in patients with operated invasive breast cancer. Methods: Two hundred thirty-four patients with ductal breast cancer who underwent surgery with curative intent were enrolled in the present study. The tumor expressions of p53, ER, PR, and HER2 were graded immunohistochemically and TP53 codon 72 polymorphism was determined by a PCR-RFLP assay using genomic DNA extracted from paraffin-embedded tissue. Results: The median age was 49 (range, 24–82) years, and 134 (57.3%) patients were premenopause at the time of diagnosis. Pathologic stages after surgery were as follows: stage I (n=77, 32.9%), stage II (n=110, 47.0%), and stage III (n=47, 20.1%). Tumor overexpression of p53 protein was observed in 59 (25.2%) patients and was associated with an unfavorable relapse-free survival (RFS) in an univariate analysis adjusted to age, stage, and menstrual status. In a multivariate analysis, p53 overexpression was an independent prognostic factor for RFS (HR=2.36; 95% CI=1.09–5.13; p=0.030). However, no associations were observed between the genotype of TP53 codon 72 polymorphism and survival or clinicopathologic characteristics. Conclusions: Overexpression of p53 protein can be considered as a prognostic factor for RFS in the breast cancer patients after surgery. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Jeong
- KyungPook National University Hospital, Daegu, Republic of Korea
| | - Y. Chae
- KyungPook National University Hospital, Daegu, Republic of Korea
| | - J. Kim
- KyungPook National University Hospital, Daegu, Republic of Korea
| | - S. Sohn
- KyungPook National University Hospital, Daegu, Republic of Korea
| | - H. Park
- KyungPook National University Hospital, Daegu, Republic of Korea
| | - J. Park
- KyungPook National University Hospital, Daegu, Republic of Korea
| | - J. Yang
- KyungPook National University Hospital, Daegu, Republic of Korea
| | - I. Park
- KyungPook National University Hospital, Daegu, Republic of Korea
| | - Y. Lee
- KyungPook National University Hospital, Daegu, Republic of Korea
| |
Collapse
|
29
|
Kim J, Chae Y, Sohn S, Kang B, Lee S, Lim K, Choi G, Baek J. -93G>A polymorphism of hMLH1 associated with prognosis for patients with colorectal cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4039 Background: Polymorphisms in the DNA repair genes may contribute to variation in DNA repair capacity, thereby affecting the risk of carcinogenesis and prognosis of colorectal cancer. Accordingly, the present study analyzed polymorphisms of DNA repair genes and their impact on the prognosis for patients with colorectal cancer. Methods: Three hundred and ninety- seven consecutive patients with curatively resected colorectal adenocarcinoma were enrolled in the present study. The genomic DNA was extracted from fresh colorectal tissue and 14 polymorphisms of DNA repair genes (XRCC1, hMLH1, ERCC2, ERCC4, VARS2[rs2074511, rs2249459], XPA, XPC, POLR2A, POLR2B, RFC1, RFC4, XAB2, DNMT3B) determined using a PCR-RFLP assay. Results: The median age of the patients was 63 years (range, 21–85), and 218 (54.9%) patients had colon cancer and 179 (45.1%) patients rectal cancer. Pathologic stages after surgery were as follows: stage 0/I (n=86, 21.7%), stage II (n=146, 36.8%), stage III (n=145, 36.5%), and stage IV (n=20, 5.0%). Multivariate survival analysis including stage, differentiation, age, and CEA level showed that the survival for the patients with the -93AA genotype of hMLH1 was worse than for the patients with the combined -93GG and GA genotype (overall survival: hazard ratio [HR]=2.953, 95% Confidential Interval [CI], 1.273–6.850, P=0.012; disease-free survival: HR=2.299, 95% CI, 1.417–3.730, P=0.001), whereas the other polymorphisms were not associated with survival. Conclusions: The -93G>A polymorphism of hMLH1 was found to be an independent prognostic marker for patients with colorectal cancer. Accordingly, in addition to the pathologic stage, the analysis of -93G>A polymorphism of hMLH1 can help identify patient subgroups at high risk of a poor disease outcome. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - Y. Chae
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - S. Sohn
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - B. Kang
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - S. Lee
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - K. Lim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - G. Choi
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - J. Baek
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| |
Collapse
|
30
|
Park H, Jung J, Eun Y, Kim J, Chae Y, Kim J, Sohn S, Park J, Yang J, Lee Y. Prognostic impact of polymorphisms of caspase genes on survival in patients with operated invasive ductal breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22020 Background: Since the apoptosis induced by caspases may play a role in the prognosis of breast cancer, the present study analyzed the polymorphisms of caspase genes and their impact on the survival in patients with operated invasive ductal breast cancer. Methods: Two hundred eighty patients with breast cancer who underwent surgery with curative intent were enrolled in the present study. The genomic DNA was extracted from paraffin-embedded tissue, and 7 single nucleotide polymorphisms (SNPs) of 6 caspase genes were determined using a PCR-RFLP assay. Results: The median age was 49 (range, 24–82) years, and 157 (56.1%) patients were premenopause at the time of diagnosis. Thirty-six (12.9%) patients underwent breast-conserving surgery. Pathologic stages after surgery were as follows: stage I (n=86, 30.7%), stage II (n=129, 46.1%), and stage III (n=63, 22.5%). Among the target SNPs, CASP6 (rs2301717, +5095G>T) and CASP7 (rs11593766, +11G>T) were found to correlate with relapse-free survival (RFS) after curative surgery in an univariate analysis adjusted to age, stage, histological grade, and the immunohistochemical expression of estrogen receptor and HER2. Meanwhile, multivariate analysis showed that the combined GT and TT genotype of CASP6 (rs2301717) was associated with a better RFS than the GG genotype (HR=0.39; 95% CI=0.19–0.79; p=0.009). However, there was no significant association with overall survival. Conclusions: The CASP6 (rs2301717) polymorphism may be considered as a possible prognostic factor for survival in patients with operated invasive breast cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Park
- Kyungpook National University Hospital, Daegu, Republic of Korea; Hyosung Medical Center, Daegu, Republic of Korea
| | - J. Jung
- Kyungpook National University Hospital, Daegu, Republic of Korea; Hyosung Medical Center, Daegu, Republic of Korea
| | - Y. Eun
- Kyungpook National University Hospital, Daegu, Republic of Korea; Hyosung Medical Center, Daegu, Republic of Korea
| | - J. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Hyosung Medical Center, Daegu, Republic of Korea
| | - Y. Chae
- Kyungpook National University Hospital, Daegu, Republic of Korea; Hyosung Medical Center, Daegu, Republic of Korea
| | - J. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Hyosung Medical Center, Daegu, Republic of Korea
| | - S. Sohn
- Kyungpook National University Hospital, Daegu, Republic of Korea; Hyosung Medical Center, Daegu, Republic of Korea
| | - J. Park
- Kyungpook National University Hospital, Daegu, Republic of Korea; Hyosung Medical Center, Daegu, Republic of Korea
| | - J. Yang
- Kyungpook National University Hospital, Daegu, Republic of Korea; Hyosung Medical Center, Daegu, Republic of Korea
| | - Y. Lee
- Kyungpook National University Hospital, Daegu, Republic of Korea; Hyosung Medical Center, Daegu, Republic of Korea
| |
Collapse
|
31
|
Chae Y, Kim J, Sohn S, Kim S, Lee S, Moon J, Jeon S, Cho Y, Choi G, Jun S. RIPK1 gene polymorphism as a prognostic marker for survival in patients with colorectal cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15078] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15078 Background: Since apoptosis plays a key role in cancer progression, we hypothesized that single nucleotide polymorphisms (SNPs) of apoptosis-related gene can affect survival after curative resection in patients with colorectal cancer. Patients and Methods: Three hundred and ninety seven patients with colorectal cancer who underwent surgery with curative intent were enrolled in the present study. The genomic DNA was extracted from fresh colorectal mucosal tissue, and the 19 SNPs of 15 apoptosis-related genes (CASP3, CASP6–10, FAS, FAS ligand [FASLG], TNSFR1A, TNSFR10B, RIPK1, BCL2, BCL2 ligand [BCL2L], TP53, and PTGS2) were determined using a PCR-RFLP assay. Results: The median age of the patients was 63 years (range, 21–85), and 218 (54.9%) patients had colon cancer and 179 (45.1%) patients rectal cancer. Pathologic stages after surgery were as follows: stage 0/I (n=86, 21.7%), stage II (n=146, 36.8%), stage III (n=145, 36.5%), and stage IV (n=20, 5.0%). Multivariate survival analysis including pathologic stage, differentiation, age, and CEA level showed that relapse-free survival for the patients with the GA+AA genotype of RIPK1 (Receptor interacting serine/threonine kinase 1) +83G>A (rs2272990) was worse than for the patients with the GG genotype (hazard ratio [HR]=1.66, 95% confidence interval [CI]=1.03–2.68, p=0.038). However, no associations were observed between the polymorphisms and overall survival (OS) in a multivariate analysis. Conclusions: RIPK1 gene polymorphism can be considered as a possible prognostic marker for survival after curative resection in patient with colorectal cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Chae
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - J. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - S. Sohn
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - S. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - S. Lee
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - J. Moon
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - S. Jeon
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - Y. Cho
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - G. Choi
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - S. Jun
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| |
Collapse
|
32
|
Song H, Kim J, Do Y, Lee W, Ryu S, Kim I, Sohn S. The clinical significance of oophorectomy in gastric patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15646 Background: The oophorectomy in isolated metastasis of ovary can lead to long term survival in patients with gastric cancer, but the clinical significance of oophorectomy in stage IV gastric cancer patients is not known well in this time. Methods: We reviewed the medical record of the 55 gastric cancer patients who were metastasis or recurrent in ovary at Dongsan Medical Center, Kimyung University School of Medicine, Daegu, Korea from 1985 to 2008. Results: Twenty-one patients were metastasis to ovary at the time of diagnosis of gastric cancer, and 34 patients were recurrent in ovary after the gastric resection. The mean age was 45.3 ± 11.6 years in metastatic cancer and 46.8 ±12.6 years in recurrent cancer patients. The stage at the time of gastric resection in 34 recurrent patients were I in 3, II in 1, III in 18, and IV in 10. Adjuvant chemotherapy were performed in 26 (76.5%) patients. Oophorectomy were performed in 33 (97.1%) of recurrent cancer, and 17 (81.0%) of metastatic cancer. The 1-year and 2-year survival rate of metastatic cancer were 14.7%, and 0%, and 1-year, 2-year, and 3-year survival rate of recurrent cancer were 47.2%, 18.1%, and 0%, respectively. The median survival duration of metastatic cancer were 8.9 ±1.0 months, and recurrent cancer were 11.4 ±2.3 months. Recurrent cancer were better survival than metastatic cancer patients (p=0.014). The long-term survival (over 2 years) was noted in 5 patients of recurrent cancer patients. The stage of gastric cancer was correlated to overall survival time in total patients (p=0.028). But, the relapse-free survival time after gastrectomy is the only factor to predict survival duration after oophorectomy in recurrent cancer patients (p=0.029). Age, stage of gastric cancer, extent of involvement of ovary, and systemic chemotherapy were not related to survival time of recurrent cancer patients. Conclusions: The survival time in patients with oophorectomy in recurrent gastric cancer was correlated to relapse-free survival time after gastric resection. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Song
- Dongsan Medical Center, Daegu, Republic of Korea; Fatima General Hospital, Daegu, Republic of Korea
| | - J. Kim
- Dongsan Medical Center, Daegu, Republic of Korea; Fatima General Hospital, Daegu, Republic of Korea
| | - Y. Do
- Dongsan Medical Center, Daegu, Republic of Korea; Fatima General Hospital, Daegu, Republic of Korea
| | - W. Lee
- Dongsan Medical Center, Daegu, Republic of Korea; Fatima General Hospital, Daegu, Republic of Korea
| | - S. Ryu
- Dongsan Medical Center, Daegu, Republic of Korea; Fatima General Hospital, Daegu, Republic of Korea
| | - I. Kim
- Dongsan Medical Center, Daegu, Republic of Korea; Fatima General Hospital, Daegu, Republic of Korea
| | - S. Sohn
- Dongsan Medical Center, Daegu, Republic of Korea; Fatima General Hospital, Daegu, Republic of Korea
| |
Collapse
|
33
|
Kim S, Kim J, Chae Y, Sohn S, Moon J, Kang B, Chung H, Yu W, Baek J. Prognostic impact of the NFKB1 insertion/deletion promoter polymorphism on survival in patients with surgically resected gastric cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15638 Background: The present study analyzed the functional insertion/deletion polymorphism in the promoter region of NKFB1 gene and their impact on the prognosis for patients with gastric adenocarcinoma. Methods: Five hundred and three consecutive patients with surgically resected gastric adenocarcinoma were enrolled in the present study. The genomic DNA was extracted from paraffin-embedded tissue and the -94 insertion/deletion ATTG polymorphism of NFKB1 determined using a PCR- RFLP assay. Results: The NFKB1 promoter gene polymorphism was successfully amplified in 97.8% of the cases. There were no sexual differences in relation to the genotype and allele. No correlation was observed between the frequency of the genotype or allele and the T, N, or M stage. The multivariate survival analysis showed no association between the NFKB1 -94 insertion/deletion promoter polymorphism and the disease-free survival or overall survival of the patients with gastric cancer. Conclusions: The functional NFKB1 promoter polymorphism was not found to be a prognostic marker for Korean patients with surgically resected gastric adenocarcinoma. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - J. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - Y. Chae
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - S. Sohn
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - J. Moon
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - B. Kang
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - H. Chung
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - W. Yu
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| | - J. Baek
- Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea
| |
Collapse
|
34
|
Kang H, Sohn S, Kim J, Park S, Hwang Y, Jang S, Kim D, Jung K. Serum Eosinophil Cationic Protein, a Useful Follow-up Marker in Baker's Asthma. J Allergy Clin Immunol 2009. [DOI: 10.1016/j.jaci.2008.12.904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Kang S, Lee ES, Choi B, Lim HC, Chun M, Lee S, Sohn S. Effects of irradiation on cytokine production in a mouse model of Behçet's disease. Clin Exp Rheumatol 2009; 27:54-63. [PMID: 19327230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
OBJECTIVE Low-dose whole-body irradiation is known to have anti-inflammatory effects. The objectives of this study were to verify that cytokine augmentation is induced by irradiation in vivo, and to assess the effectiveness of radiation in treating Behçet's disease (BD). METHODS Whole-body and half-body irradiation with single doses of 10cGy, 2Gy and 10Gy were delivered to normal mice, and cytokine and chemokine levels were analyzed in PBMC and sera. BD-like mice were treated with low-dose, half-body 10cGy irradiation. RESULTS In normal mice, PBMC cytokine mRNA levels peaked four days after irradiation. Of the cytokines and chemokines examined, the levels of IL-4, IL-6, IL-12p40, TNF-alpha, TGF-b, MIP-1alpha and IL-18 were all influenced by radiation treatment. Of these, IL-4, an ameliorating factor for BD, was the most elevated following low-dose irradiation (10cGy group). FACS analysis showed intracellular IL-4-staining of 7.24+/-0.92% of PBMC from irradiated mice compared to 1.3+/-0.1% from non-irradiated, normal mice (p<0.005). Serum IL-4 levels were also significantly increased (6.08+/-1.7 pg/ml) relative to control (1.83+/-0.8; p<0.005). CONCLUSION Augmentation of cytokine production may contribute to the anti-inflammatory effects of low dose irradiation and amelioration of BD symptoms in this mouse model.
Collapse
Affiliation(s)
- S Kang
- Department of Radiation Oncology, Ajou University School of Medicine, Suwon, South Korea
| | | | | | | | | | | | | |
Collapse
|
36
|
Shim J, Byun HO, Lee YD, Lee ES, Sohn S. Interleukin-6 small interfering RNA improved the herpes simplex virus-induced systemic inflammation in vivo Behcet’s disease-like mouse model. Gene Ther 2008; 16:415-25. [DOI: 10.1038/gt.2008.180] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|
37
|
Sohn SH, Cho EJ, Son WJ, Lee CY. Diagnosis of bovine freemartinism by fluorescence in situ hybridization on interphase nuclei using a bovine Y chromosome-specific DNA probe. Theriogenology 2008; 68:1003-11. [PMID: 17870153 DOI: 10.1016/j.theriogenology.2007.06.022] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2007] [Accepted: 06/30/2007] [Indexed: 11/19/2022]
Abstract
A heifer co-twin to a bull, in most cases, is a sterile freemartin which needs to be identified and culled from replacement stock. Various methods are available for the diagnosis of freemartinism, but none is ideal in terms of speed, sensitivity, or specificity. The present study was thus conducted to develop and validate a satisfactory fluorescence in situ hybridization procedure on interphase nuclei (I-FISH) for identifying the bovine XX/XY-karyotypic chimerism, the hallmark of freemartinism. A 190-bp DNA FISH probe containing the bovine male-specific BC1.2 DNA sequence was synthesized and labeled with digoxigenin by PCR. The FISH was performed on metaphase spreads and interphase nuclei of blood lymphocytes. Upon FISH, the probe expectedly bound to the nucleus of the male cell or to a region of the p12 locus of the Y chromosome. Twenty-four young heterosexual twins (Holstein-Friesian and Korean Cattle breeds; 10 pairs and 4 singletons) were analyzed in the present study; all but three exhibited the XX/XY-karyotypic chimerism to varying extents in both I-FISH and karyotyping. One heifer was identified to have 100% XX cells by both analyses, whereas two bulls were judged as 100% XY- and XX/XY-chimeric karyotypes by karyotyping and I-FISH, respectively. Nevertheless, the ratios of the XY to XX cells in these animals were very similar between the two analyses. In conclusion, the present I-FISH was a rapid and reliable procedure that can be used for early-life diagnosis of bovine freemartinism.
Collapse
Affiliation(s)
- S H Sohn
- Department of Animal Science and Biotechnology, Jinju National University, Jinju, Republic of Korea.
| | | | | | | |
Collapse
|
38
|
Schöffski O, Sohn S, Happich M. [Overall burden to society caused by hyperkinetic syndrome (HKS) and attention deficit hyperactivity disorder (ADHD)]. Gesundheitswesen 2008; 70:398-403. [PMID: 18729028 DOI: 10.1055/s-0028-1082049] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
OBJECTIVE The purpose of this work was to provide an analysis of medical costs for HKS/ADHD on the basis of a cost-of-illness study. METHODS A systematic literature review concerning the direct and indirect costs of HKS/ADHD and its related implications was complemented by a special analysis of the German Federal Office of Statistics on ICD-10 F 90. RESULTS An analysis of overall medical costs by the Federal Office of Statistics results in expenses of 142 million euro in 2002 corresponding to ca. 630 euro per patient per year. These values are considerably below the values calculated for the USA. Increased indirect costs related to different implications of the indication were stated in international studies. CONCLUSION A first estimate of the direct costs for HKS/ADHS in Germany has been conducted. A reduction of the difference between the German and the US direct cost values may be expected. An increased level of the indirect costs related to HKS/ADHD may be assumed for Germany and requires further research.
Collapse
Affiliation(s)
- O Schöffski
- Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg
| | | | | |
Collapse
|
39
|
Chae Y, Kim J, Sohn S, Moon J, Kim S, Ryoo H, Bae S, Choi G, Jun S, Lee M. Prognostic impact of apoptosis-related and DNA repair gene polymorphisms in patients with advanced colorectal cancer treated with capecitabine and oxaliplatin chemotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Abstract
Double-outlet left ventricle (DOLV) is conventionally repaired with an extracardiac conduit when pulmonary stenosis is present. We report a case of surgical repair for DOLV with severe pulmonary stenosis where the right ventricular outflow tract was established using a vascular graft patch anteriorly after constructing the posterior wall with autologous tissue. This approach provides excellent hemodynamic repair without the use of an extracardiac conduit and has the major advantage of growth potential.
Collapse
Affiliation(s)
- S Sohn
- Department of Pediatrics, School of Medicine, Ewha Womans University, Seoul, 158-710, Korea.
| | | | | |
Collapse
|
41
|
Seo J, Park JS, Nam JH, Bang D, Sohn S, Lee ES, Park KS. Association of CD94/NKG2A, CD94/NKG2C, and its ligand HLA-E polymorphisms with Behcet's disease. Tissue Antigens 2007; 70:307-13. [PMID: 17767552 DOI: 10.1111/j.1399-0039.2007.00907.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Inhibitory CD94/NKG2A and activating CD94/NKG2C receptors are expressed on natural killer, CD4, and CD8 T cells and recognize human leukocyte antigen (HLA)-E, resulting in the modulation of cytotoxic activity and cytokine production. An imbalance in cytotoxic activity and cytokine production has been implicated in Behcet's disease (BD). The results of this study showed that the NKG2A c.-4258*C, c.338-90*G, and CD94 c.-134*T alleles (P= 0.015, OR = 0.8; P < 0.0001, OR = 0.5; and P= 0.034, OR = 0.8, respectively) were associated with decreased risk and that NKG2A c.284-67_-62del, c.1077*C, and the activating receptor, NKG2C c.305*T were not associated with 345 patients with BD. But a significant difference in NKG2C c.305*T was detected among BD patients with ocular lesions and arthritis (P < 0.0001, OR = 2.1 and P= 0.0001, OR = 1.8, respectively). We already showed in our previous research that HLA-E*0101 also appears to contribute to a reduction in risk through the inhibitory CD94/NKG2A-mediated immune response. This result led us to the analyses of the combined risk of the HLA-E and the NKG2A for BD. Individuals harboring HLA-E*0101, NKG2A c.-4258*C, and c.338-90*G evidenced a reduced risk of BD compared with healthy controls (21.1% vs 40.1%, P < 0.0001, OR = 0.4). By way of contrast, individuals without the HLA-E*0101, NKG2A c.-4258*C, and c.338-90*G alleles evidenced a twofold increased risk of BD (P= 0.014, OR = 2.0). Individuals without HLA-E*0101, NKG2A c.-4258*G/*G, and c.338-90*G evidenced a 4.8-fold increase in BD risk (P= 0.0002, OR = 4.8). Although the effects of these single nucleotide polymorphisms (SNPs) remain unclear, our results indicate that the SNPs of the inhibitory receptor CD94/NKG2A and its haplotypes, as well as its ligand HLA-E, are associated with BD immune systems.
Collapse
Affiliation(s)
- J Seo
- Department of Biology and Institute of Basic Science, Sungshin Women's University, 249-1 3-ga, Dongseon-dong, Sungbuk-ku, Seoul 136-742, Korea
| | | | | | | | | | | | | |
Collapse
|
42
|
Moon J, Kim J, Sohn S, Yang D, Lee J, Kim H, Shin H, Chung J, Lee W, Joo Y, Oh S. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8069] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8069 Background: The present study was conducted to evaluate the safety and efficacy of alemtuzumab plus CHOP chemotherapy for patients with peripheral T-cell lymphomas (PTCLs). Methods: Twenty patients with newly diagnosed PTCLs were enrolled. The treatment consisted of classical CHOP plus alemtuzumab (10 mg/m2 i.v on day 1 and 20 mg/m2 i.v on day 2 in the first cycle, then 30 mg/m2 i.v on day 1 in the subsequent cycles) based on 3-week intervals. Results: Thirteen complete responses (65.0%) and 3 partial responses (15.0%) were confirmed, giving an overall response rate of 80.0 %. The estimated event-free survival at 1 year was 43.3%. The most severe hematologic adverse event was neutropenia, which occurred with a grade 4 intensity in 18 patients (90.0%). Plus, febrile neutropenia was observed in 11 patients (55.0%). Five patients (25%) experienced CMV (cytomegalovirus) reactivation, while 3 patients developed CMV diseases, such as pneumonitis or retinitis. There were 2 treatment-related deaths. Conclusions: The alemtuzumab plus CHOP chemotherapy seemed to produce active antitumor activity in terms of the complete response rates in patients with PTCLs. However, since high infectious and hematologic toxicities were observed, careful monitoring and early treatment to prevent treatment-related mortality are needed. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Moon
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Gwangju, Republic of Korea; Pusan National University Hospital, Busan, Republic of Korea; Inje University Hospital, Busan, Republic of Korea; Kangbuk Samsung Hospital, Seoul, Republic of Korea
| | - J. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Gwangju, Republic of Korea; Pusan National University Hospital, Busan, Republic of Korea; Inje University Hospital, Busan, Republic of Korea; Kangbuk Samsung Hospital, Seoul, Republic of Korea
| | - S. Sohn
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Gwangju, Republic of Korea; Pusan National University Hospital, Busan, Republic of Korea; Inje University Hospital, Busan, Republic of Korea; Kangbuk Samsung Hospital, Seoul, Republic of Korea
| | - D. Yang
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Gwangju, Republic of Korea; Pusan National University Hospital, Busan, Republic of Korea; Inje University Hospital, Busan, Republic of Korea; Kangbuk Samsung Hospital, Seoul, Republic of Korea
| | - J. Lee
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Gwangju, Republic of Korea; Pusan National University Hospital, Busan, Republic of Korea; Inje University Hospital, Busan, Republic of Korea; Kangbuk Samsung Hospital, Seoul, Republic of Korea
| | - H. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Gwangju, Republic of Korea; Pusan National University Hospital, Busan, Republic of Korea; Inje University Hospital, Busan, Republic of Korea; Kangbuk Samsung Hospital, Seoul, Republic of Korea
| | - H. Shin
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Gwangju, Republic of Korea; Pusan National University Hospital, Busan, Republic of Korea; Inje University Hospital, Busan, Republic of Korea; Kangbuk Samsung Hospital, Seoul, Republic of Korea
| | - J. Chung
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Gwangju, Republic of Korea; Pusan National University Hospital, Busan, Republic of Korea; Inje University Hospital, Busan, Republic of Korea; Kangbuk Samsung Hospital, Seoul, Republic of Korea
| | - W. Lee
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Gwangju, Republic of Korea; Pusan National University Hospital, Busan, Republic of Korea; Inje University Hospital, Busan, Republic of Korea; Kangbuk Samsung Hospital, Seoul, Republic of Korea
| | - Y. Joo
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Gwangju, Republic of Korea; Pusan National University Hospital, Busan, Republic of Korea; Inje University Hospital, Busan, Republic of Korea; Kangbuk Samsung Hospital, Seoul, Republic of Korea
| | - S. Oh
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Gwangju, Republic of Korea; Pusan National University Hospital, Busan, Republic of Korea; Inje University Hospital, Busan, Republic of Korea; Kangbuk Samsung Hospital, Seoul, Republic of Korea
| |
Collapse
|
43
|
Chae Y, Kim J, Sohn S, Cho Y, Moon J, Jeon S, Park J, Lee I, Choi G, Jun S. Vascular endothelial growth factor (VEGF) gene polymorphisms associated with prognosis for patients with colorectal cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4125 Background: Vascular endothelial growth factor (VEGF) or its family may be considered to play an important role in lymphangiogenesis and lymphatic tumor spread, thereby affecting prognosis of colorectal cancer. Accordingly, the present study analyzed VEGF gene polymorphisms and their impact on the prognosis for patients with colorectal cancer. Patients and Methods: Four hundred and sixty-five consecutive patients with surgically treated colorectal adenocarcinoma were enrolled in the present study. The genomic DNA was extracted from fresh colorectal tumor tissue and 3 VEGF (-2578C > A, -634G > C, and +936C > T) gene polymorphisms determined using a PCR/DHPLC (Polymerase chain reaction/Denaturing high-performance liquid chromatography) assay. Results: The median age of the patients was 64 years (range, 21–89), and 264 (56.7%) patients had colon cancer and 201 (48.2%) patients rectal cancer. Pathologic stages evaluable (n=464) after surgery were as follows: stage I (n=79, 17.0%), stage II (n=157, 33.8%), stage III (n=157, 33.8%), and stage IV (n=71, 15.3%). Multivariate survival analysis including stage, differentiation, and CEA level showed that survival for patients with the -634CC (overall survival [OS]: hazard ratio [HR]=0.175, P<0.001; progression-free survival [PFS]: HR=0.554, P=0.040) or GC genotype (OS: HR=0.158, P<0.001; PFS: HR=0.630, P=0.044) were better than for patients with the -634GG genotype, whereas the +936TT (OS: HR=65.959, P<0.001; PFS: HR=2.823, P=0.016) or CT genotype (OS: HR=16.116, P<0.001; PFS: HR=3.507, P<0.001) were associated with a worse survival compared to the CC genotype. In haplotype analysis, the -2578A/-634G/+936T haplotype exhibited a significantly worse survival when compared to the wild -2578C/-634G/+936C haplotype (OS: HR=4.670, P<0.001; PFS: HR=3.624, P<0.001). Conclusions: VEGF gene polymorphisms were found to be an independent prognostic marker for patients with colorectal cancer. Accordingly, the analysis of VEGF gene polymorphisms can help identify patient subgroups at high risk of a poor disease outcome. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Chae
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - J. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - S. Sohn
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - Y. Cho
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - J. Moon
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - S. Jeon
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - J. Park
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - I. Lee
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - G. Choi
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - S. Jun
- Kyungpook National University Hospital, Daegu, Republic of Korea
| |
Collapse
|
44
|
Koliogiannis D, Fersis N, Sohn S, Kaul S. Zirkulierende Tumorzellen: Quantitative Genexpressionsanalyse bei Patienten mit Brustkrebs. Geburtshilfe Frauenheilkd 2007. [DOI: 10.1055/s-2007-984658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
45
|
Abstract
The nonclassical human leukocyte antigen (HLA)-E and -G molecules have previously been shown to inhibit natural killer- and cytotoxic T-lymphocyte-mediated cell lysis and have also been shown to prevent the proliferation of CD4 T cells and secrete cytokines that appear to be important in the modulation of the Behcet's disease (BD) immune systems. Polymorphisms in the HLA-E and HLA-G genes have been associated with differential expression and function. Thus, we conducted an analysis of the HLA-E and HLA-G alleles using Amplification Refractory Mutation System-polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism techniques in a study comprising 312 patients with BD and 486 controls. The HLA-E*0101 and HLA-G*010101 alleles were associated with a reduced risk of BD (P = 0.0002, odds ratio (OR) = 0.7 and P = 0.002, OR = 0.7, respectively). By way of contrast, the variants HLA-E*010302, HLA-G*010102, G*0105N alleles and 3741_3754ins14bp were all associated with an increased risk of BD (P < 0.0001, OR = 1.6; P = 0.002, OR = 1.8; P = 0.024, OR = 2.0 and P = 0.003, OR = 1.4, respectively). Individuals carrying both the HLA-E*0101 and the HLA-G*010101 alleles evidenced significantly lower frequency in the patients than in the controls (35.6% vs 49.6%; P < 0.0001, OR = 0.6). These results indicate that variant HLA-E and HLA-G molecules appear to function independently and synergistically, increasing the risk of BD, and may result in an imbalance of lymphocytic functions, which may culminate in the development of BD.
Collapse
Affiliation(s)
- K S Park
- Department of Biology, Sungshin Women's University, Seoul, South Korea.
| | | | | | | | | | | |
Collapse
|
46
|
Cho Y, Baek J, Sohn S, Chae Y, Kim D, Kim J, Yang D, Kim Y, Lee J, Kim H. Pilot remission induction therapy with idarubicin, plus intensified dose of Ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.16516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
16516 Background: The sensitization of leukemic cells with hematopoietic growth factors can enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML). Intensified remission induction (RI) therapy can also improve the treatment results for AML. Therefore, the current trial attempted to evaluate the efficacy and toxicity of granulocyte colony-stimulating factor (G-CSF) priming and a dose intensification of Ara-C in RI chemotherapy for AML. Methods: A total of 29 patients with newly diagnosed AML received G-CSF-priming RI chemotherapy consisting of idarubicin (12 mg/m2, D1–3), G-CSF (150 ug/m2, D3–8), and Ara-C (500 mg/m2, bid, D4–8), and the outcomes were compared with those for a historical group treated with a standard regimen consisting of idarubicin (12 mg/m2, D1–3) and Ara-C (100 mg/m2, D1–7). Results: There was no difference in the sex, age, subtype, and cytogenetic risk between the two groups. The complete remission (CR) rate and treatment-related mortality (TRM) were 72% and 17% for G-CSF-primed group and 71% and 10% for the historical group, respectively (p = 0.89 and p = 0.32). The time to neutrophil and platelet recovery did not differ significantly between the two groups (25 days vs. 24 days, p=0.17; 24 days vs. 23 days, p = 0.23, respectively). Similarly, the duration of fever was also not significantly different (5 days vs. 7 days, p = 0.58). Thirteen patients (45%) experienced fever and 5 patients (17%) manifested skin rashes during the G-CSF priming. After a median follow-up of 336 days, the 1-year overall survival (OS), disease-free survival (DFS), and event-free survival (EFS) rates were 72% vs. 63% (p = 0.83), 74% vs. 56% (p = 0.059), and 53% vs. 38% (p = 0.32), respectively. Conclusion: The G-CSF-priming RI regimen with an intensified dose of Ara-C did not show a superior efficacy when compared with a standard regimen, yet did produce a slightly longer DFS. Therefore, the sensitization of leukemic cells with growth factors and dose intensification would only seem to be a clinically applicable means to enhance the efficacy of RI chemotherapy in selected patients with AML, thereby warranting further studies focusing on specific subgroups of AML patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Cho
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Hwasun, Republic of Korea
| | - J. Baek
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Hwasun, Republic of Korea
| | - S. Sohn
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Hwasun, Republic of Korea
| | - Y. Chae
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Hwasun, Republic of Korea
| | - D. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Hwasun, Republic of Korea
| | - J. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Hwasun, Republic of Korea
| | - D. Yang
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Hwasun, Republic of Korea
| | - Y. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Hwasun, Republic of Korea
| | - J. Lee
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Hwasun, Republic of Korea
| | - H. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Chonnam National University Hospital, Hwasun, Republic of Korea
| |
Collapse
|
47
|
Baek J, Kim J, Chae Y, Cho Y, Sohn S, Choi Y, Shin H, Chung J, Cho G, Yu W. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14037 Background: Several studies have shown the efficacy of capecitabine and irinotecan combination chemotherapy for advanced colorectal cancer, while no results have yet been reported for advanced gastric cancer. Accordingly, the current study evaluated the efficacy and safety of a combination regimen of capecitabine plus irinotecan in patients with advanced gastric cancer. Methods: Patients with previously untreated metastatic or recurrent, measurable gastric cancer received oral capecitabine 1000 mg/m2 twice daily from day 1 to 14 and intravenous irinotecan 100 mg/m2 on days 1 and 8, based on a 3-week cycle. Results: Forty-one patients were enrolled in the current study, among whom 38 were assessable for efficacy and 40 assessable for toxicity. Three complete responses and 16 partial responses were confirmed, giving an overall response rate of 46.3%. At a median follow-up of 269 days, the median time to progression and overall survival were 5.1 months and 8.6 months, respectively. Grade 3/4 neutropenia occurred in 4 patients and grade 3 febrile neutropenia was observed in 2 patients. Grade 3 diarrhea and grade 2 hand-foot syndrome occurred in 6 patients and 8 patients, respectively. Conclusions: The combination of capecitabine and irinotecan was found to be well tolerated and effective in patients with advanced gastric cancer. Accordingly, this regimen can be regarded as an important first-line treatment option for advanced gastric cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Baek
- Kyungpook National University Hospital, Daegu, Republic of Korea; Pusan National University Hospital, Pusan, Republic of Korea
| | - J. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Pusan National University Hospital, Pusan, Republic of Korea
| | - Y. Chae
- Kyungpook National University Hospital, Daegu, Republic of Korea; Pusan National University Hospital, Pusan, Republic of Korea
| | - Y. Cho
- Kyungpook National University Hospital, Daegu, Republic of Korea; Pusan National University Hospital, Pusan, Republic of Korea
| | - S. Sohn
- Kyungpook National University Hospital, Daegu, Republic of Korea; Pusan National University Hospital, Pusan, Republic of Korea
| | - Y. Choi
- Kyungpook National University Hospital, Daegu, Republic of Korea; Pusan National University Hospital, Pusan, Republic of Korea
| | - H. Shin
- Kyungpook National University Hospital, Daegu, Republic of Korea; Pusan National University Hospital, Pusan, Republic of Korea
| | - J. Chung
- Kyungpook National University Hospital, Daegu, Republic of Korea; Pusan National University Hospital, Pusan, Republic of Korea
| | - G. Cho
- Kyungpook National University Hospital, Daegu, Republic of Korea; Pusan National University Hospital, Pusan, Republic of Korea
| | - W. Yu
- Kyungpook National University Hospital, Daegu, Republic of Korea; Pusan National University Hospital, Pusan, Republic of Korea
| |
Collapse
|
48
|
Chae Y, Kim J, Baek J, Cho E, Sohn S, Chung H, Yu W, Lee M, Bae H. Vascular endothelial growth factor (VEGF) polymorphism is associated with prognosis of patients with gastric cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4019 Background: Recent studies demonstrated that the expression of vascular endothelial growth factor (VEGF) family had a prognostic significance in patients with gastric cancer. The present study analyzed VEGF polymorphism and its impact on prognosis in patients with gastric cancer. Methods: Five hundred three consecutive patients with surgically resected gastric adenocarcinoma at a single institution between January 2000 and December 2001 were enrolled into the study. Genomic DNA was extracted from paraffin-embedded tumor tissue and four VEGF (-460T > C, +405C > G, 936C> T, and -1154G > A) genotypes were determined using a PCR-RFLP assay. Results: The median age of patients was 60.0 years (range, 25–83 years), and 337 (67.0%) patients were male. Pathologic stages after resection were as follows: stage 0 (n=6, 1.2%), stage I (n=277, 55.1%), stage II (n=105, 20.9%), stage III (n=74, 14.7%), and stage IV (n=41, 8.2%). The estimated 5-year disease-free survival (DFS) rates according to stage were significantly different (p < 0.0001). Three VEGF polymorphisms (+405C > G, 936C, and -1154G > A > T) were not associated with survival of patients, while -460T > C polymorphism had a prognostic significance. In patients with early stage gastric cancer (stage 0 or 1, n=283), the estimated 5-year DFS and carcinoma-specific survival (CSS) for patients with homozygous genotype (CC or TT) of -460T > C were superior to those for heterozygous genotype (CT) (98.1% versus 90.3%, p=0.0047; 98.1% versus 92.5%, p=0.0284). In Cox multivariate regression, stage and VEGF -460T > C genotype were an independent prognostic factors for both DFS (p=0.007; p=0.010) and CSS (p=0.013; p=0.038). Conclusions: VEGF -460T > C polymorphism was found to be an independent prognostic marker for patients with curatively resected early stage gastric adenocarcinoma. Accordingly, VEGF -460T > C polymorphism can help to identify patients with unfavorable clinical outcome and thereby may be useful to refine therapeutic decisions in early stage gastric cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Chae
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - J. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - J. Baek
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - E. Cho
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - S. Sohn
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - H. Chung
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - W. Yu
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - M. Lee
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - H. Bae
- Kyungpook National University Hospital, Daegu, Republic of Korea
| |
Collapse
|
49
|
Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M. Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study. Dermatology 2006; 212:137-44. [PMID: 16484820 DOI: 10.1159/000090654] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2005] [Accepted: 08/19/2005] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND There is little information concerning the costs of psoriasis and patients' quality of life (QoL) in Germany. OBJECTIVE To obtain data on the annual costs and QoL(to follow in a further publication) of patients with moderate to severe plaque psoriasis. METHODS Between October 2003 and February 2004, six office-based dermatologists and eight dermatology outpatient departments retrospectively documented cost-of-illness data from a societal cost perspective in 184 patients over a 12-month period. Patients were stratified into three subgroups according to their treatment scheme. RESULTS Mean total costs amounted to euro 6,709 per patient and year. The mean PASI score was 18.2 and PBSA 28.9%. Annual costs were highest with euro 8,831 in high-need patients. They also showed the highest PASI score (22.2). CONCLUSION Moderate to severe plaque psoriasis is associated with tremendous costs, particularly in patients not adequately controlled by conventional therapies, while the outcomes of patients were unsatisfactory.
Collapse
Affiliation(s)
- S Sohn
- Chair for Health Management, University of Erlangen-Nuremberg, Lange Gasse 20, DE-90403 Nuremberg, Germany.
| | | | | | | | | | | | | |
Collapse
|
50
|
Sohn S, Kwon H, Kim K, Park C, Kim H, Kim S, Park H, Park H, Jeong Y, Kim S, Jang Y, Kim Y, Cho S, Min K, Kim Y. Association between Genetic Variations in FGF receptors and Airway Hyperresponsiveness. J Allergy Clin Immunol 2006. [DOI: 10.1016/j.jaci.2005.12.633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|